Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E, Kalogeras KT, Kotsantis I, Koliou GA, Manousou K, Wirtz R, Veltrup E, Patsea H, Poulakaki N, Dionysopoulos D, Pervana S, Gogas H, Koutras A, Pentheroudakis G, Christodoulou C, Linardou H, Pavlakis K, Koletsa T, Pectasides D, Zagouri F, Fountzilas G. Razis E, et al. Among authors: kalogeras kt. Clin Breast Cancer. 2020 Feb;20(1):e36-e53. doi: 10.1016/j.clbc.2019.08.008. Epub 2019 Sep 5. Clin Breast Cancer. 2020. PMID: 31699671
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras AK, Kalogeras KT, Dimopoulos MA, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G; Hellenic Cooperative Oncology Group (HeCOG). Koutras AK, et al. Among authors: kalogeras kt. Br J Cancer. 2008 Dec 2;99(11):1775-85. doi: 10.1038/sj.bjc.6604769. Epub 2008 Nov 4. Br J Cancer. 2008. PMID: 18985033 Free PMC article.
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: kalogeras kt. Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31. Breast Cancer Res Treat. 2009. PMID: 18668363 Clinical Trial.
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: kalogeras kt. Breast Cancer Res Treat. 2011 May;127(1):179-93. doi: 10.1007/s10549-011-1427-0. Epub 2011 Mar 9. Breast Cancer Res Treat. 2011. PMID: 21390496 Free article.
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P. Fountzilas G, et al. Among authors: kalogeras kt. J Transl Med. 2012 Jan 12;10:10. doi: 10.1186/1479-5876-10-10. J Transl Med. 2012. PMID: 22240029 Free PMC article.
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G. Razis E, et al. Among authors: kalogeras kt. Clin Breast Cancer. 2012 Jun;12(3):183-93. doi: 10.1016/j.clbc.2012.03.006. Clin Breast Cancer. 2012. PMID: 22607768
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G, Kotoula V, Eleftheraki AG, Tsolaki E, Wirtz RM, Kalogeras KT, Batistatou A, Bobos M, Dimopoulos MA, Timotheadou E, Gogas H, Christodoulou C, Papadopoulou K, Efstratiou I, Scopa CD, Papaspyrou I, Vlachodimitropoulos D, Linardou H, Samantas E, Pectasides D, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: kalogeras kt. PLoS One. 2013 Jul 29;8(7):e70634. doi: 10.1371/journal.pone.0070634. Print 2013. PLoS One. 2013. PMID: 23923010 Free PMC article.
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G. Koutras A, et al. Among authors: kalogeras kt. J Transl Med. 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0. J Transl Med. 2015. PMID: 26021752 Free PMC article.
Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H, Kalogeras KT, Kronenwett R, Alexopoulou Z, Wirtz RM, Zagouri F, Scopa CD, Gogas H, Petraki K, Christodoulou C, Pavlakis K, Koutras AK, Samantas E, Patsea H, Pectasides D, Bafaloukos D, Fountzilas G. Linardou H, et al. Among authors: kalogeras kt. Anticancer Res. 2015 Jul;35(7):4023-36. Anticancer Res. 2015. PMID: 26124351 Clinical Trial.
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G. Papaxoinis G, et al. Among authors: kalogeras kt. PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015. PLoS One. 2015. PMID: 26452060 Free PMC article. Clinical Trial.
96 results